Pharmaceutical

MSD ventures into fibroblast therapies with $1.9bn deal with Mestag

The deal allows MSD to license one or more therapies against inflammatory diseases developed using the UK biotech’s fibroblast platform.

Oct 10, 2024 - 04:00
MSD ventures into fibroblast therapies with $1.9bn deal with Mestag
The deal allows MSD to license one or more therapies against inflammatory diseases developed using the UK biotech’s fibroblast platform.
Read the original article

Tags:

Previous Article

Anima Biotech’s machine learning programme ‘reveals new mRNA drug targets’

Next Article

Emergent to donate 20,000 Narcan doses to fight opioid overdoses, CEO says

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: For-profit biomedical institute, backed by billionaires, launches in Cambridge to speed drug discovery

STAT+: For-profit biomedical institute, backed by billi...

Jan 14, 2024

Health records don’t always show when patients are dead. One researcher is trying to change that

Health records don’t always show when patients are dead...

Dec 15, 2023

Risk adjusted net present value: What is the current va...

Mar 13, 2024